Scholars@Duke publication: Utilizing Pre-Clinical Melanoma Models to Design Rational Combinatorial Immunotherapy Regimens : Lessons Learned from Targeting the TGF-beta Signaling Pathway.

Utilizing Pre-Clinical Melanoma Models to Design Rational Combinatorial Immunotherapy Regimens : Lessons Learned from Targeting the TGF-beta Signaling Pathway.

Publication , Conference

Hanks, BA

Duke Scholars

Author Brent A. Hanks Medicine, Medical Oncology

Contributor Brent A. Hanks Medicine, Medical Oncology

Location

Washington, DC

Conference Name

2017 Melanoma Research Alliance Annual Meeting

Citation

APA

Chicago

ICMJE

MLA

NLM

Hanks, B. A. (n.d.). Utilizing Pre-Clinical Melanoma Models to Design Rational Combinatorial Immunotherapy Regimens : Lessons Learned from Targeting the TGF-beta Signaling Pathway. Presented at the 2017 Melanoma Research Alliance Annual Meeting, Washington, DC.

Hanks, B. A. “Utilizing Pre-Clinical Melanoma Models to Design Rational Combinatorial Immunotherapy Regimens : Lessons Learned from Targeting the TGF-beta Signaling Pathway.,” n.d.

Hanks BA. Utilizing Pre-Clinical Melanoma Models to Design Rational Combinatorial Immunotherapy Regimens : Lessons Learned from Targeting the TGF-beta Signaling Pathway. In.

Hanks, B. A. Utilizing Pre-Clinical Melanoma Models to Design Rational Combinatorial Immunotherapy Regimens : Lessons Learned from Targeting the TGF-beta Signaling Pathway.

Hanks BA. Utilizing Pre-Clinical Melanoma Models to Design Rational Combinatorial Immunotherapy Regimens : Lessons Learned from Targeting the TGF-beta Signaling Pathway.

Location

Washington, DC

Conference Name

2017 Melanoma Research Alliance Annual Meeting